Cargando…
Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease
OBJECTIVE: To use a robust statistical methodology to develop and validate clinical rating scales quantifying longitudinal motor and cognitive dysfunction in sporadic Creutzfeldt-Jakob disease (sCJD) at the bedside. METHODS: Rasch analysis was used to iteratively construct interval scales measuring...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921594/ https://www.ncbi.nlm.nih.gov/pubmed/35022318 http://dx.doi.org/10.1136/jnnp-2021-327722 |
_version_ | 1784669356194529280 |
---|---|
author | Nihat, Akin Mok, Tze How Odd, Hans Thompson, Andrew Geoffrey Bourne Caine, Diana McNiven, Kirsty O'Donnell, Veronica Tesfamichael, Selam Rudge, Peter Collinge, John Mead, Simon |
author_facet | Nihat, Akin Mok, Tze How Odd, Hans Thompson, Andrew Geoffrey Bourne Caine, Diana McNiven, Kirsty O'Donnell, Veronica Tesfamichael, Selam Rudge, Peter Collinge, John Mead, Simon |
author_sort | Nihat, Akin |
collection | PubMed |
description | OBJECTIVE: To use a robust statistical methodology to develop and validate clinical rating scales quantifying longitudinal motor and cognitive dysfunction in sporadic Creutzfeldt-Jakob disease (sCJD) at the bedside. METHODS: Rasch analysis was used to iteratively construct interval scales measuring composite cognitive and motor dysfunction from pooled bedside neurocognitive examinations collected as part of the prospective National Prion Monitoring Cohort study, October 2008–December 2016. A longitudinal clinical examination dataset constructed from 528 patients with sCJD, comprising 1030 Motor Scale and 757 Cognitive Scale scores over 130 patient-years of study, was used to demonstrate scale utility. RESULTS: The Rasch-derived Motor Scale consists of 8 items, including assessments reliant on pyramidal, extrapyramidal and cerebellar systems. The Cognitive Scale comprises 6 items, and includes measures of executive function, language, visual perception and memory. Both scales are unidimensional, perform independently of age or gender and have excellent inter-rater reliability. They can be completed in minutes at the bedside, as part of a normal neurocognitive examination. A composite Examination Scale can be derived by averaging both scores. Several scale uses, in measuring longitudinal change, prognosis and phenotypic heterogeneity are illustrated. CONCLUSIONS: These two novel sCJD Motor and Cognitive Scales and the composite Examination Scale should prove useful to objectively measure phenotypic and clinical change in future clinical trials and for patient stratification. This statistical approach can help to overcome obstacles to assessing clinical change in rapidly progressive, multisystem conditions with limited longitudinal follow-up. |
format | Online Article Text |
id | pubmed-8921594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-89215942022-03-25 Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease Nihat, Akin Mok, Tze How Odd, Hans Thompson, Andrew Geoffrey Bourne Caine, Diana McNiven, Kirsty O'Donnell, Veronica Tesfamichael, Selam Rudge, Peter Collinge, John Mead, Simon J Neurol Neurosurg Psychiatry Neurodegeneration OBJECTIVE: To use a robust statistical methodology to develop and validate clinical rating scales quantifying longitudinal motor and cognitive dysfunction in sporadic Creutzfeldt-Jakob disease (sCJD) at the bedside. METHODS: Rasch analysis was used to iteratively construct interval scales measuring composite cognitive and motor dysfunction from pooled bedside neurocognitive examinations collected as part of the prospective National Prion Monitoring Cohort study, October 2008–December 2016. A longitudinal clinical examination dataset constructed from 528 patients with sCJD, comprising 1030 Motor Scale and 757 Cognitive Scale scores over 130 patient-years of study, was used to demonstrate scale utility. RESULTS: The Rasch-derived Motor Scale consists of 8 items, including assessments reliant on pyramidal, extrapyramidal and cerebellar systems. The Cognitive Scale comprises 6 items, and includes measures of executive function, language, visual perception and memory. Both scales are unidimensional, perform independently of age or gender and have excellent inter-rater reliability. They can be completed in minutes at the bedside, as part of a normal neurocognitive examination. A composite Examination Scale can be derived by averaging both scores. Several scale uses, in measuring longitudinal change, prognosis and phenotypic heterogeneity are illustrated. CONCLUSIONS: These two novel sCJD Motor and Cognitive Scales and the composite Examination Scale should prove useful to objectively measure phenotypic and clinical change in future clinical trials and for patient stratification. This statistical approach can help to overcome obstacles to assessing clinical change in rapidly progressive, multisystem conditions with limited longitudinal follow-up. BMJ Publishing Group 2022-04 2022-01-12 /pmc/articles/PMC8921594/ /pubmed/35022318 http://dx.doi.org/10.1136/jnnp-2021-327722 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Neurodegeneration Nihat, Akin Mok, Tze How Odd, Hans Thompson, Andrew Geoffrey Bourne Caine, Diana McNiven, Kirsty O'Donnell, Veronica Tesfamichael, Selam Rudge, Peter Collinge, John Mead, Simon Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease |
title | Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease |
title_full | Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease |
title_fullStr | Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease |
title_full_unstemmed | Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease |
title_short | Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease |
title_sort | development of novel clinical examination scales for the measurement of disease severity in creutzfeldt-jakob disease |
topic | Neurodegeneration |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921594/ https://www.ncbi.nlm.nih.gov/pubmed/35022318 http://dx.doi.org/10.1136/jnnp-2021-327722 |
work_keys_str_mv | AT nihatakin developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT moktzehow developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT oddhans developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT thompsonandrewgeoffreybourne developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT cainediana developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT mcnivenkirsty developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT odonnellveronica developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT tesfamichaelselam developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT rudgepeter developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT collingejohn developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease AT meadsimon developmentofnovelclinicalexaminationscalesforthemeasurementofdiseaseseverityincreutzfeldtjakobdisease |